Division of Sangamo BioSciences Inc./Ceregene Inc.
Latest From Ceregene Inc.
NCI study uses Bellicum's CAR T cell safety switch; Innocutis licenses Sitavig from BioAlliance; Portola initiates andexanet alfa Phase III; Alcobra enrolls first Phase III patient; Cardium becomes Taxus Cardium; Sangamo prices $100m offering; Alexza completes $45m private placement; and Oxygen raising $52m.
As gene therapy moves closer toward becoming an established therapeutic mode, developers have focused mainly on ophthalmology and monogenic rare diseases, but improvements in vector technology are pointing the field toward targets in the central nervous system. The latest entrant is Voyager Therapeutics Inc., which launched in February with a $45 million Series A commitment from Third Rock Ventures and a lead program in Parkinson's disease.
Sangamo used 2013 to progress its pipeline, to raise money and to acquire a company. The momentum carried into the first quarter of 2014 with the Biogen partnership and a jump in share price that suggested that investors finally may have bought into the gene therapy company’s unique story.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August through September 2013.
- Gene Therapy, Cell Therapy
- Large Molecule
- Medical Devices
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Sangamo BioSciences Inc.
- Senior Management
- Raymond T Bartus, PhD, EVP & CSO
- Contact Info
Phone: (858) 458-8800
9381 Judicial Dr.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.